HK1080390A1 - Pharmaceutical composition for thrombin peptide derivatives - Google Patents

Pharmaceutical composition for thrombin peptide derivatives

Info

Publication number
HK1080390A1
HK1080390A1 HK06101502A HK06101502A HK1080390A1 HK 1080390 A1 HK1080390 A1 HK 1080390A1 HK 06101502 A HK06101502 A HK 06101502A HK 06101502 A HK06101502 A HK 06101502A HK 1080390 A1 HK1080390 A1 HK 1080390A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
thrombin peptide
peptide derivatives
thrombin
disclosed
Prior art date
Application number
HK06101502A
Other languages
English (en)
Inventor
David M Hobson
Darrell H Carney
Andrew Po Kwan Tang
Original Assignee
Orthologic Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthologic Corp filed Critical Orthologic Corp
Publication of HK1080390A1 publication Critical patent/HK1080390A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK06101502A 2003-12-31 2006-02-03 Pharmaceutical composition for thrombin peptide derivatives HK1080390A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53373003P 2003-12-31 2003-12-31

Publications (1)

Publication Number Publication Date
HK1080390A1 true HK1080390A1 (en) 2006-04-28

Family

ID=34652502

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101502A HK1080390A1 (en) 2003-12-31 2006-02-03 Pharmaceutical composition for thrombin peptide derivatives

Country Status (14)

Country Link
US (2) US7291596B2 (de)
EP (1) EP1559431B1 (de)
JP (1) JP5044829B2 (de)
CN (1) CN1913917B (de)
AT (1) ATE357928T1 (de)
AU (1) AU2004312090B2 (de)
CA (1) CA2551525C (de)
DE (1) DE602004005564T2 (de)
DK (1) DK1559431T3 (de)
ES (1) ES2287660T3 (de)
HK (1) HK1080390A1 (de)
PL (1) PL1559431T3 (de)
PT (1) PT1559431E (de)
WO (1) WO2005065706A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539800B1 (de) * 2002-07-02 2007-05-23 Orthologic Corp. Dimere von thrombinpeptidderivaten
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
TWI486168B (zh) * 2006-09-22 2015-06-01 Univ Texas 治療內皮功能不良之方法
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
AU2009229402A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
CA2722621A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
CA2719940A1 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
EP2280722A2 (de) * 2008-03-26 2011-02-09 Orthologic Corp. Verfahren zur behandlung von degenerativen erkrankungen
WO2010033862A2 (en) * 2008-09-19 2010-03-25 The Board Of Regents, The University Of Texas System Methods for treating cancer
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2539435A2 (de) 2010-02-23 2013-01-02 Corning Incorporated Modifizierte substrate für den schutz von peptidimmobilisierten oberflächen aus gammastrahlungsabbau
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
JP6297158B2 (ja) * 2013-10-03 2018-03-20 ルイス・アルベルト・アメスティカ・サラサール Ｍｆ、ｕｆ、ｐｆ、ｍｕｆ、及びフェノール樹脂から選択される１つ又は複数の樹脂；並びに１つを超える可溶性銅塩を含む、殺生物性樹脂組成物
ES2981634T3 (es) 2014-05-15 2024-10-09 Insmed Incorporated Métodos para tratar infecciones micobacterianas pulmonares no tuberculosas
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CN105879010A (zh) * 2015-01-17 2016-08-24 内蒙古天奇生物科技有限公司 一种能促进创伤愈合减轻创后瘢痕的多肽组合物及其制备方法
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
CA3135790A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019612A1 (de) * 1980-05-22 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim Stabilisiertes thrombinpraeparat
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
JP2000229882A (ja) * 1998-12-10 2000-08-22 Sankyo Co Ltd 修飾シクロデキストリン含有トロンビン水性液剤
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
AU2002239965B2 (en) 2000-07-19 2007-01-04 Orthologic Corp. Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
CN100350971C (zh) * 2000-07-19 2007-11-28 奥索洛吉艾斯有限公司 用凝血酶肽衍生物刺激骨生长
CN1458974A (zh) 2000-07-20 2003-11-26 德克萨斯系统大学董事会 用非蛋白质水解激活的凝血酶受体的激动剂刺激软骨生长
EP1333824B1 (de) * 2000-11-17 2005-09-07 Warner-Lambert Company LLC Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
MXPA03007619A (es) * 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
WO2003013569A2 (en) 2001-07-27 2003-02-20 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
ATE504311T1 (de) 2002-01-16 2011-04-15 Capstone Therapeutics Corp Thrombin-derivierten peptiden zur förderung von herzgewebsreparatur
ES2377959T3 (es) * 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
EP1539800B1 (de) 2002-07-02 2007-05-23 Orthologic Corp. Dimere von thrombinpeptidderivaten

Also Published As

Publication number Publication date
CN1913917B (zh) 2012-02-01
US20090054343A1 (en) 2009-02-26
EP1559431A1 (de) 2005-08-03
DK1559431T3 (da) 2007-07-30
EP1559431B1 (de) 2007-03-28
DE602004005564T2 (de) 2007-12-13
CN1913917A (zh) 2007-02-14
ATE357928T1 (de) 2007-04-15
CA2551525C (en) 2013-02-19
AU2004312090A1 (en) 2005-07-21
DE602004005564D1 (de) 2007-05-10
ES2287660T3 (es) 2007-12-16
AU2004312090B2 (en) 2008-08-14
WO2005065706A1 (en) 2005-07-21
US7875588B2 (en) 2011-01-25
US20050203017A1 (en) 2005-09-15
US7291596B2 (en) 2007-11-06
JP5044829B2 (ja) 2012-10-10
PL1559431T3 (pl) 2007-10-31
PT1559431E (pt) 2007-07-02
JP2007518724A (ja) 2007-07-12
CA2551525A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
HK1080390A1 (en) Pharmaceutical composition for thrombin peptide derivatives
EP2269608A3 (de) Pharmazeutische Zusammensetzungen welche Monoamin-Aufnahme-Neurotrransmitter-Reuptake-Inhibitoren und Acetylcholinesterase Inhibitoren enthalten
HK1100166A1 (en) Effervescent oral opiate dosage form
HK1046105A1 (zh) 抑制胰高血糖素的方法
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
WO2003072195A3 (en) Method for administering glp-1 molecules
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
WO2004032866A3 (en) Therapeutic formulations
IL161834A0 (en) Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
EP1064966A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
WO2004041190A3 (en) Composition for the treatment of macular degenration
WO2005062894A3 (en) Co-administration of dopamine-receptor binding compounds
AU2003251643A1 (en) Pharmaceutical compositions containing keto-acids for endoperitoneal administration
EP1064948A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
EP1099446A3 (de) Ein ZNS-penetrierende NK-1 rezeptorantagonist und ein Angstlösendes oder antidepressives Mittel enthaltende Zusammensetzung zur Behandlung von Depression und Angst
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation
AU2003235931A1 (en) Vintoperol-containing medicinal composition for transdermal administration

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131230